Transcranial Magnetic Stimulation for Parkinson's (NCT06835595)
Magnetic pulses detect thinking problems
- Trial ID
- NCT06835595
- Official Title
- Transcranial Magnetic Stimulation (TMS) Related Measures as Biomarker of Cognitive Impairment in Parkinson's Disease (PD)
- Goal
- Magnetic pulses detect thinking problems
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Azienda Sanitaria Universitaria Integrata del Trentino
- Study Type
- INTERVENTIONAL
- Enrollment
- 52 participants
- Conditions
- Parkinson Disease
- Interventions
- Transcranial Magnetic Stimulation
Summary For Families
The goal is to find noninvasive brain measures that signal cognitive impairment in Parkinson's, so thinking problems can be detected or tracked earlier and more reliably. The approach uses transcranial magnetic stimulation, which delivers brief magnetic pulses to the scalp to probe cortical excitability, connectivity, and plasticity, recording responses that might link to memory and attention changes while participants also get neuropsychological testing. Tests are done while people remain on their usual antiparkinsonian medications, kept stable for at least four weeks, so results reflect typical treatment effects. Adults 18 and older with idiopathic PD who can complete neuropsychological testing and give informed consent are eligible, while people with dementia by MDS criteria, implanted metal or electronic devices, a history of seizures, pregnancy, or certain seizure‑risk medications are excluded.
Locations
- SC Clinica Neurologica - Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI), Trieste, Friuli Venezia Giulia, Italy
- UOC Neuroriabilitazione - Azienda Sanitaria dell'Alto Adige, Sterzing, Trentino-Alto Adige, Italy
- UOC Neurologia - Azienda Provinciale per i Servizi Sanitari (APSS), Trento, Trentino-Alto Adige, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying Transcranial Magnetic Stimulation. The goal is to find noninvasive brain measures that signal cognitive impairment in Parkinson's, so thinking problems can be detected or tracked earlier and more reliably. The approach uses transcranial magnetic stimulation, which delivers brief magnetic pulses to the scalp to probe cortical excitability, connectivity, and plasticity, recording responses that might link to memory and attention changes while participants also get neuropsychological testing. Tests are done while people remain on their usual antiparkinsonian medications, kept stable for at least four weeks, so results reflect typical treatment effects. Adults 18 and older with idiopathic PD who can complete neuropsychological testing and give informed consent are eligible, while people with dementia by MDS criteria, implanted metal or electronic devices, a history of seizures, pregnancy, or certain seizure‑risk medications are excluded.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 3 locations.
- Does it cost anything to join?
- You are never charged a fee to join a legitimate clinical trial, and the study treatment and study-specific tests are provided by the trial sponsor at no charge. In the US, routine care you would receive anyway can still be billed to you or your insurance; coverage rules differ by country, and trials in the UK and Canada usually run through public health systems. Travel, parking, and time are real costs, and some trials reimburse them while others do not. Before enrolling, ask the study coordinator to explain in writing what is and is not covered.
- How long does the trial last?
- This trial is estimated to last approximately 3 years and 4 months.
- Can I leave the trial if I change my mind?
- Yes. You can withdraw from any clinical trial at any time, for any reason, without affecting your standard medical care. Trials are voluntary by law. The team may ask if you are willing to do a brief exit visit so they can collect safety information, but you are not obligated.
- Can my spouse or care partner come with me to visits?
- In most cases yes, and it is often encouraged. Care partners can help with notes, questions, and getting home safely after a long visit. Some study assessments do need to happen one on one, but care partners are usually welcome for the rest of the appointment.
- Will I get a placebo in this trial?
- Everyone in this trial receives the experimental treatment. There is no placebo group.
- How many visits does this trial involve?
- Participants are assessed at T0 (baseline), after T1 (one year), T2 (two years), and T3 (three years).